A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed and dated written informed consent.
• Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml/min/1.73m2, as measured at least once in the last 3 months.
• Stable PD prescription, as determined by investigators.
• Stable dose of RAAS blockade if on a medication within this class for the last 30 days.
Locations
Other Locations
Canada
Toronto General Hospital
RECRUITING
Toronto
Contact Information
Primary
Vesta Lai
vesta.lai@uhn.ca
416-340-4800
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 20
Treatments
Experimental: Empagliflozin
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto